Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 170Neoplasms 66Carcinoma, Non-Small-Cell Lung 49Neoplasm Metastasis 37Unspecified Adult Solid Tumor, Protocol Specific 25Ovarian Neoplasms 21Breast Neoplasms 21Urinary Bladder Neoplasms 20Cholangiocarcinoma 20Lymphoma 19Colorectal Neoplasms 18Lymphoma, Non-Hodgkin 17Lung Neoplasms 17Sarcoma 16Hodgkin Disease 14Fallopian Tube Neoplasms 14Biliary Tract Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Gallbladder Neoplasms 11Colonic Neoplasms 11Carcinoma, Ovarian Epithelial 11Stomach Neoplasms 10Recurrence 10Solid Tumors 9Bile Duct Neoplasms 8Adenocarcinoma 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Rectal Neoplasms 7Melanoma 7

Interventions

Imatinib Mesylate 12Sunitinib 4Leucovorin 3ripretinib 2nilotinib 2avapritinib 2Oxaliplatin 2Irinotecan 2Ipilimumab 2Fluorouracil 2CTLA-4 Antigen 2umbralisib 1tanespimycin 1spartalizumab 1sargramostim 1ribociclib 1repaglinide 1regorafenib 1pexidartinib 1olverembatinib 1binimetinib 1alvocidib 1Thalidomide 1TH 302 1TAS-116 1Pharmacogenomic Testing 1OSI 930 1Midazolam 1IDRX-42 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Stromal Tumors × Gemcitabine × Clear all
NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡